{"title": "Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation", "doi": "10.1101/2020.02.11.944462", "citation_id": "2020.02.11.944462v1", "date": "2020-02-15", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.02.11.944462", "abstract": "<h3>Abstract</h3>\n<p>The outbreak of a novel betacoronavirus (2019-nCov) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for urgently needed vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure (MCM) development we determined a 3.5 \u00c5-resolution cryo-EM structure of the 2019-nCoV S trimer in the prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation. We also show biophysical and structural evidence that the 2019-nCoV S binds ACE2 with higher affinity than SARS-CoV S. Additionally we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to nCoV-2019 S, suggesting antibody cross-reactivity may be limited between the two virus RBDs. The atomic-resolution structure of 2019-nCoV S should enable rapid development and evaluation of MCMs to address the ongoing public health crisis.</p>", "twitter_description": "The outbreak of a novel betacoronavirus (2019-nCov) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for urgently needed vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure (MCM) development we determined a 3.5 \u00c5-resolution cryo-EM structure of the 2019-nCoV S trimer in the prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation. We also show biophysical and structural evidence that the 2019-nCoV S binds ACE2 with higher affinity than SARS-CoV S. Additionally we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to nCoV-2019 S, suggesting antibody cross-reactivity may be limited between the two virus RBDs. The atomic-resolution structure of 2019-nCoV S should enable rapid development and evaluation of MCMs to address the ongoing public health crisis.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.02.11.944462v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.02.11.944462v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.02.11.944462v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/02/15/2020.02.11.944462.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.02.11.944462v1", "access_rights": "restricted", "authors": ["Daniel Wrapp", "Nianshuang Wang", "Kizzmekia S. Corbett", "Jory A. Goldsmith", "Ching-Lin Hsieh", "Olubukola Abiona", "Barney S. Graham", "Jason S. McLellan"]}